Clinical Trials Logo

Filter by:
NCT ID: NCT05300152 Recruiting - Drug Effect Clinical Trials

Pulpotomy Medications in Primary Teeth

Start date: October 2, 2022
Phase: N/A
Study type: Interventional

this study is aimed to evaluate and compare the pulp response to ACTIVA BioACTIVE Base/Liner and MTA as pulpotomy medication in primary teeth.

NCT ID: NCT05299047 Recruiting - Pain Cancer Clinical Trials

Fluoroscopic Anterior Approach Versus Ultrasound Guided Superior Hypogastric Plexus Neurolysis in Cancer Pelvic Pain

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

Cancer related pelvic pain can be debilitating and difficult to treat. Superior hypogastric plexus neurolysis (SHPN) is considered to be an option for adequately relieving pain, with fewer side effects and improving the quality of life

NCT ID: NCT05298670 Recruiting - Multiple Sclerosis Clinical Trials

Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

Start date: February 1, 2022
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the effect of Metformin as add- on therapy for improving the outcome in RRMS patients.

NCT ID: NCT05297981 Recruiting - Postoperative Pain Clinical Trials

Quadratus Lumborum Block Versus Erector Spinae Plane Block for Postoperative Analgesia in Laparoscopic Surgeries

Start date: November 23, 2021
Phase: N/A
Study type: Interventional

Postoperative pain after laparoscopic abdominal surgeries can be severe. Despite multimodal analgesia protocols, administration of high doses of opioids is often required hindering early mobilization and discharge of the patient from the day surgery setting and is suboptimal in an Early Recovery after Surgery setting. Settings and design A prospective randomized double blinded study. Aim To evaluate and compare the analgesic effect of ultrasound-guided erector spinae plane (ESP) block with ultrasound-guided posterior Quadratus Lumborum Block in laparoscopic abdominal surgeries. Patients and methods This randomized prospective study will be carried for 6 months on adult patients with American Society of Anesthesiologists (ASA) Physical Status Class I and II, aged between 30 and 60 years.

NCT ID: NCT05297214 Recruiting - Acute Kidney Injury Clinical Trials

A Study of Acute Kidney Injury in Children at Sohag University Hospital

Start date: January 1, 2022
Phase:
Study type: Observational

Acute kidney injury (AKI) has been traditionally defined as an abrupt loss of kidney function leading to a rapid decline in the glomerular filtration rate (GFR), accumulation of waste products such as blood urea nitrogen (BUN) and creatinine, and dysregulation of extracellular volume and electrolyte homeostasis . Acute kidney injury (AKI) is a very common condition, especially among hospitalized patients. this work aims to study the demographics, etiology, clinical characteristics, and outcome of acute kidney injury in children in Sohag University Hospital - Pediatrics Department.

NCT ID: NCT05293327 Recruiting - Clinical trials for Laryngeal Squamous Cell Carcinoma

IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate

IMP3PCNA
Start date: June 2022
Phase:
Study type: Observational

Laryngeal cancer is responsible for 2-5% of all new cancer cases worldwide. Squamous cell carcinoma of the larynx (LSCC) is the most common malignant tumor of the larynx, accounting for 85-90% of all laryngeal malignancies. Despite significant therapeutic developments in recent decades, increases in patients' 5-year survival rates are still minimal , which is likely due to late-stage diagnosis and other complex factors. Therefore, to improve the outcome, timely diagnosis, selection of the most appropriate therapy, and an adequate follow-up approach is needed. The insulin-like growth factor II m-RNA-binding protein 3 (IMP3) is a new biomarker that may be implicated in the carcinogenesis of various malignancies, including head and neck squamous cell carcinoma. IMP3 normally expressed in embryonic tissue but decreases after birth and is no longer detectable in adult tissue With the exception of a few tissues. As a result, IMP3 is expressed only in tumors and not in neighboring normal tissues. Proliferating Cell Nuclear Antigen (PCNA) is a nuclear protein that acts as a cell proliferation marker. In most forms of solid malignancies, such as colorectal cancer and breast cancer, PCNA is closely linked to prognosis and survival. In this study, hoping to improve diagnosis of LSCC and assess prognosis better by using both IMP3 and PCNA biomarkers. As IMP3 may have a role in cell growth and proliferation and PCNA is a marker of cell proliferation; studying the association between both markers in laryngeal carcinoma is recommended.

NCT ID: NCT05291845 Recruiting - Clinical trials for Human Papilloma Virus

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

Start date: April 3, 2022
Phase: Phase 2
Study type: Interventional

To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy

NCT ID: NCT05291455 Recruiting - Epilepsy Clinical Trials

Lacosamide in Neonatal Status Epilepticus

Start date: March 1, 2022
Phase: Phase 3
Study type: Interventional

Lacosamide in neonatal status epilepticus

NCT ID: NCT05290896 Recruiting - Cataract Clinical Trials

Correlations Between Lens Star and Phacoemulsification.

Start date: February 20, 2022
Phase: N/A
Study type: Interventional

To assess correlations between lens star biometry parameters and phacoemulsification in clinical practice.

NCT ID: NCT05289453 Recruiting - Glaucoma Clinical Trials

Phacoemulsification in Acute Congestive Glaucoma

Start date: February 20, 2022
Phase: N/A
Study type: Interventional

Acute primary angle closure (APAC) is usually caused by an abrupt closure of the trabecular meshwork in the anterior chamber angle that leads to a sudden rise in intraocular pressure (IOP). APAC is a subgroup of angle closure disease characterised by a sudden onset of headache, blurred vision, seeing halos around lights, corneal oedema, mid-dilated pupil, eye pain and redness. Asian also has a much higher incident rate of APAC compare to the Caucasian population - with the crude incidence rate of 12.2 and 10.4 per 100,000 people per year in the above 30-year-old population of Singapore and Hong Kong, respectively . This is higher than the average incidence rate of 3.9-4.1 cases per 100,000 people per year in the European regions . In APAC, both LPI and primary lens extraction by phacoemulsification and intraocular lens implant (phaco/IOL) were demonstrated to be effective to control IOP elevation. The latter has been shown to be the more effective treatment than LPI for IOP reduction at the early and mid-term IOP control. Together with the advancement of phaco/IOL technique, primary lens extraction is the more popular choice of treatment nowadays. However, operating on an eye with early aborted APAC is technically challenging and may increase the risk of complications because of the presence of corneal oedema, inflammation, shallow anterior chamber, floppy iris and unstable lens. Furthermore, "the best time window" for performing lens extraction after an APAC attack remains uncertain. The long-term results (e.g. more than 5 years) of early lens extraction compared to the conventional LPI are also unknown. In this study, we summarise the approach of treating APAC at the initial acute stage and review the studies that consider IOP control in the mid and long term. We would also touch on the role of goniosynechialysis, trabeculectomy and endoscopic cyclophotocoagulation in treating APAC, as well as considering the economic aspect of treatment. Aim of the study: to evaluate the safety and efficacy of phacoemulsificatiojn in cases of acute congestive glaucoma